CPDC Celebrates Successful FDA Inspection!

August 23, 2019 CPDC
« 1 of 6 »

Hamilton, Ontario, August 16, 2019 – The Centre for Probe Development and Commercialization’s Senior Leadership Team took time on Friday afternoon to celebrate with their Hamilton staff on the McMaster University campus at the famous Willy Dog Hot Dog cart. Over 60 staff attended the lunch time event on a great summer day!  The event was held to show appreciation to our staff for the effort put into the preparation for CPDC’s FDA audit held in July 2019. Special treats were sent to our offsite locations in Toronto and Ottawa, as well as to the night shift staff in Hamilton, to ensure the whole company was included in the event.

CPDC’s President and CEO, Dr. Joe McCann commented at the event that “CPDC is committed to maintaining industry leading quality standards and implementing continued quality improvements. We are very grateful and appreciative of our staff who all embrace this approach and who put significant effort into the preparation for the audit.  We are extremely pleased to announce that no observations were received at the conclusion of the inspection.  CPDC extends its gratitude to our clients who supported us during the inspection.” CPDC is also inspected by Health Canada and has maintained a compliant rating since 2009.

About CPDC

The Centre for Probe Development and Commercialization (CPDC) is a private, not-for-profit company “Dedicated to improving patient’s lives by advancing drugs for the diagnosis and treatment of diseases.”  Created in 2008, with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University and the Ontario Institute for Cancer Research (OICR), CPDC has become a global leader in the discovery, development and commercialization of next-generation radiopharmaceuticals. With an established a pipeline of products and a robust and reliable manufacturing unit, CPDC supplies innovative diagnostic and therapeutic radiopharmaceuticals that are used daily in Canada and around the world. CPDC currently employs over 110 staff in Hamilton, Toronto and Ottawa. For more information about CPDC, please visit: www.imagingprobes.ca

Contacts

Centre for Probe Development and Commercialization

Angela Lauretani, 905 525-9140, ext. 21212

cpdc@imagingprobes.ca

More news from CPDC

CARI Blog #1: Radiopharmaceuticals: a new class of drugs for cancer patients, and a new road for Canada to lead global life sciences

The role of radiopharmaceuticals in health care may still be quite a mystery for many Canadians, but this area has a tremendous therapeutic and commercial potential in our country. Canada is already a global leader in radioisotope-based health care technologies, meaning it has the strengths to also become a world leader in bringing related novel

Centre for Probe Development & Commercialization (CPDC) Appoints New Interim CEO

Hamilton, Ontario (October 22, 2020) ‐ Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, is announcing today that the Company’s Board of Directors has appointed Bruno Paquin as Interim Chief Executive Officer, effective November 2, 2020. Justyna Kelly, CPDC’s outgoing CEO said, “Since joining CPDC,

Pave the road to successful commercialization of your radiopharmaceutical innovation with CARI – The CPDC & adMare Radiopharmaceutical Initiative

If you are an academic researcher or a biotech company looking to pave the road to successful commercialization of your radiopharmaceutical innovation, join us on October 15th, 2020. What is CARI? CARI is a collaboration between The Centre for Probe Development and Commercialization (CPDC) and adMare BioInnovations (adMare) where we will bring respective resources together to

For more information contact us at: